{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:56:50Z","timestamp":1783000610807,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102004","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T02:05:01Z","timestamp":1581300301000},"page":"102004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6947-3661","authenticated-orcid":false,"given":"Antonio","family":"Marangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Vicenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Forlivesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Calabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marchioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Forgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianola","family":"Stenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gajofatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Donata","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2020.102004_bib0001","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1080\/14740338.2017.1388371","article-title":"Drugs approved for the treatment of multiple sclerosis: review of their safety profile","volume":"16","author":"Auricchio","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2020.102004_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ejhpharm-2017-001286","article-title":"Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis","volume":"26","author":"Bartolome-Garcia","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.msard.2020.102004_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jocn.2015.12.044","article-title":"Predictors of first-line treatment persistence in a portuguese cohort of relapsing-remitting multiple sclerosis","volume":"33","author":"Correia","year":"2016","journal-title":"J Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2020.102004_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2020.102004_bib0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.msard.2018.08.004","article-title":"Outcomes and treatment management of a french cohort suffering from multiple sclerosis: a retrospective epidemiological study","volume":"25","author":"Defer","year":"2018","journal-title":"Mult. Scler Relat. Disord"},{"key":"10.1016\/j.msard.2020.102004_bib0006","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-018-2429-1","article-title":"The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations","volume":"74","author":"Eriksson","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2020.102004_bib0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: a population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102004_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/03007995.2018.1451311","article-title":"First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an italian real-life multicenter study on persistence","volume":"34","author":"Ferraro","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.msard.2020.102004_bib0009","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","volume":"6","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2020.102004_bib0010","unstructured":"Gazzetta ufficiale italiana 18-3-2016. nota 65. farmaci per la sclerosi multipla. Available from: http:\/\/www.gazzettaufficiale.it\/do\/atto\/serie_generale\/caricaPdf?cdimg=16A0214800100010110001&dgu=2016-03-18&art.dataPubblicazioneGazzetta=2016-03-18&art.codiceRedazionale=16A02148&art.num=1&art.tiposerie=SG."},{"issue":"3","key":"10.1016\/j.msard.2020.102004_bib0011","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3111\/13696998.2012.667027","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the U.S","volume":"15","author":"Ivanova","year":"2012","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.msard.2020.102004_bib0012","first-page":"844","article-title":"Real-World adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J Manag Care Spec. Pharm."},{"issue":"4","key":"10.1016\/j.msard.2020.102004_bib0013","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102004_bib0014","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jns.2018.03.018","article-title":"Real-world persistence with fingolimod for the treatment of multiple sclerosis: a systematic review and meta-analysis","volume":"388","author":"Kantor","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.msard.2020.102004_bib0015","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2020.102004_bib0016","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","article-title":"A multicentRE observational analysiS of PErsistenCe to treatment in the new multiple sclerosis era: the respect study","volume":"265","author":"Lanzillo","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102004_bib0017","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00415-017-8595-8","article-title":"Persistence to oral disease-modifying therapies in multiple sclerosis patients","volume":"264","author":"Lattanzi","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102004_bib0018","article-title":"Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice","volume":"2","author":"Longbrake","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"11","key":"10.1016\/j.msard.2020.102004_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113371","article-title":"Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial","volume":"9","author":"Massacesi","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2020.102004_bib0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/ene.12990","article-title":"A population-based study comparing multiple sclerosis clinic users and non-users in british columbia, canada","volume":"23","author":"McKay","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102004_bib0021","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S138263","article-title":"Persistence to disease-modifying therapies for multiple sclerosis in a canadian cohort","volume":"11","author":"Melesse","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.msard.2020.102004_bib0022","article-title":"Use and cost of disease-modifying therapies by sonya slifka study participants: has anything really changed since 2000 and 2009","volume":"5","author":"Minden","year":"2019","journal-title":"Mult Scler J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102004_bib0023","article-title":"The use of disease-modifying therapies in multiple sclerosis: principles and current evidence","year":"2017","journal-title":"A consensus paper. Updated"},{"key":"10.1016\/j.msard.2020.102004_bib0024","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cen3.12411","article-title":"Prevalence, treatments and medical cost of multiple sclerosis inJapan based on analysis of a health insurance claims database","volume":"8","author":"Ogino","year":"2017","journal-title":"Clinical and Experimental Neuroimmunology"},{"issue":"2","key":"10.1016\/j.msard.2020.102004_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2020.102004_bib0026","unstructured":"Available from: https:\/\/www.tuttitalia.it\/veneto\/statistiche\/popolazione-andamento-demografico, 2018."},{"key":"10.1016\/j.msard.2020.102004_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14656566.2018.1446944","article-title":"Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients","volume":"19","author":"Rommer","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.msard.2020.102004_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.msard.2018.07.012","article-title":"Use of the new oral disease-modifying therapies for multiple sclerosis in british columbia, canada: the first five-years","volume":"25","author":"Setayeshgar","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102004_bib0029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","article-title":"Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study","volume":"27","author":"Setayeshgar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2020.102004_bib0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis: a review of approved medications","volume":"23 Suppl","author":"Torkildsen","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2020.102004_bib0031","unstructured":"World Health Organization, 2003. Adherence to long-term therapies-evidence for action. 2003. Available from: http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_introduction.pdf\u3009."},{"key":"10.1016\/j.msard.2020.102004_bib0032","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/ane.12705","article-title":"BETAPATH study group. baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis","volume":"136","author":"Zettl","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.msard.2020.102004_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123824","article-title":"Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: a 18-year observational cohort study","volume":"10","author":"Zhornitsky","year":"2015","journal-title":"PLoS ONE"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:55Z","timestamp":1761900475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"alternative-id":["S2211034820300808"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102004","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102004"}}